Skip to content
Clinical Trials – home
Verifiedinfo

Clinexpert Kft.

Hungary Kaszasdulo Utca 5, 1033 Budapest, Hungary

  • 36 trials recruiting
  • Colitis ulcerative · Dermatitis atopic · Crohn's disease
  • Adults and children

About Specializations

Clinexpert Kft. in Budapest, Hungary specialises in clinical trials of conditions such as Colitis ulcerative, Dermatitis atopic, Crohn's disease, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Asthma

The medical center is at the forefront of research in asthma, focusing on the long-term safety and efficacy of innovative treatments. The center's work in this area aims to improve the quality of life for patients with moderate to severe asthma.

  • Long-term safety evaluation of amlitelimab
  • Improving treatment tolerability

Through its research, the center contributes to the development of more effective asthma management strategies, ensuring better patient outcomes.

Migraine

Specializing in pediatric migraine, the center conducts extensive research on the safety and efficacy of treatments like atogepant. This research is crucial for developing preventive strategies for young patients.

  • Long-term safety of atogepant in children
  • Prevention of episodic migraine

The center's work in this field is instrumental in shaping future therapeutic approaches for pediatric migraine management.

Ulcerative Colitis

Research at the center focuses on innovative treatments for ulcerative colitis, aiming to improve bowel urgency and overall disease management. The center evaluates new therapies to enhance patient care.

  • Mirikizumab for bowel urgency
  • Comparative studies of PB016 and Entyvio®

These studies are pivotal in advancing treatment options and improving the quality of life for patients with ulcerative colitis.

Crohn's Disease

The center is dedicated to advancing the treatment of Crohn's Disease through comparative studies of novel therapies. This research is essential for patients who have not responded to traditional treatments.

  • Risankizumab vs. ustekinumab efficacy
  • Long-term safety of risankizumab

By exploring new therapeutic avenues, the center aims to provide more effective solutions for managing Crohn's Disease.

Cardiovascular Diseases

Focusing on hypertriglyceridemia and related cardiovascular conditions, the center evaluates the impact of treatments like olezarsen on triglyceride levels, contributing to cardiovascular health advancements.

  • Olezarsen's effect on triglycerides
  • Management of atherosclerosis

This research is vital for developing strategies to reduce cardiovascular risk and improve patient outcomes.

Chronic Obstructive Pulmonary Disease (COPD)

The center's research on COPD focuses on reducing exacerbations and improving patient management through treatments like benralizumab, addressing a critical need in respiratory care.

  • Benralizumab's impact on COPD exacerbations
  • Management of severe COPD

These efforts are crucial for enhancing the quality of life for patients with severe respiratory conditions.

Endometriosis

Research at the center addresses endometriosis-related pain, evaluating the efficacy of treatments like OG-6219. This work is essential for improving pain management in affected women.

  • OG-6219 efficacy in pain reduction
  • Safety and tolerability assessments

The center's research contributes to better therapeutic options for managing endometriosis symptoms.

Atopic Dermatitis

Specializing in atopic dermatitis, the center evaluates treatments like rocatinlimab and upadacitinib, focusing on safety and dose flexibility to improve patient care.

  • Rocatinlimab safety in adolescents
  • Upadacitinib dose flexibility

This research is pivotal in developing effective management strategies for atopic dermatitis.

Major Depressive Disorder (MDD)

The center's research in major depressive disorder focuses on adjunctive therapies like SEP-363856, aiming to enhance treatment efficacy for patients with inadequate responses to standard antidepressants.

  • SEP-363856 as adjunctive therapy
  • Improving antidepressant response

These studies are crucial for advancing treatment options and improving mental health outcomes.

Primary Dysmenorrhea

Research at the center explores the efficacy of natural treatments like Vitex agnus-castus for primary dysmenorrhea, offering alternative solutions for menstrual pain management.

  • Vitex agnus-castus efficacy
  • Alternative pain management strategies

This research is vital for providing non-pharmacological options for women experiencing menstrual pain.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Kaszasdulo Utca 51033 BudapestHungary
Recruiting now
36 trials
Conditions studied
53
Partner status
Verified

More sites in BudapestHungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

123 clinical trials

Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:HungaryHungary
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting
Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.